



Half-yearly financial statements 30 June 2018

Quantum Genomics

30/06/2018





Interim Balance sheet Assets

Quantum Genomics

Registered Number : 48799664700029

Assets		Period			Previous period	
		Gross Amount	Depr. or Allow.	Net amount	at : 31/12/2017	
Uncalled subscribed capital						
Fixed assets	Intangible fixed assets	Start up costs				
		Research and development costs				
		Franchises, patents and similar assets	134 283	47 608	86 674	90 945
		Goodwill				
		Other intangible fixed assets				
		Intangible assets in progress				
	Advance payments on intangible fixed assets					
	TOTAL	134 283	47 608	86 674	90 945	
	Tangible fixed assets	Land				
		Buildings				
Industrial fixtures and equipment		22 911	15 017	7 894	464	
Other tangible fixed assets		108 748	57 430	51 317	51 747	
Tangible fixed assets in progress						
Advance payments on tangible fixed assets						
TOTAL	131 659	72 448	59 211	52 211		
Financial fixed assets	Investments measured using the equity method					
	Other investments					
	Loans to group and related companies					
	Investments held in portfolio for the long term					
	Other investments	357 865	103 886	253 979	258 052	
	Loans					
Other financial assets	37 531		37 531	37 531		
TOTAL	395 396	103 886	291 510	295 584		
Total fixed assets		661 339	223 942	437 396	438 741	
Current assets	Inventories	Raw material and supplies	138 532		138 532	188 888
		Work in progress (goods)				
		Work in progress (services)				
		Finished goods and by-production				
		Merchandise				
	TOTAL	138 532		138 532	188 888	
	Advances to suppliers					
Receivables	Trade accounts receivable	2 387 246		2 387 246	1 613 976	
	Other receivables					
	Unpaid called capital					
TOTAL	2 387 246		2 387 246	1 613 976		
Other	Marketable securities (of which own shares :)	8 003		8 003	5 001 505	
	Cash instruments	5 962 711		5 962 711	6 087 727	
	Available funds					
TOTAL	5 970 715		5 970 715	11 089 232		
Prepaid expenses	740 216			583 437		
Total current assets		9 236 709		9 236 709	13 475 535	
Deferred charges						
Premiums on redemption of borrowings						
Exchange rate differences assets		276		276	2 853	
Total assets		9 898 325	223 942	9 674 382	13 917 130	

Quantum Genomics

Liabilities		Period	Previous period
Shareholder's funds	Share capital (of which paid up : 4 619 654)	4 619 654	4 393 771
	Share premiums (mergers, contributions)	31 275 570	30 790 466
	Revaluation variance		
	Equity reserve		
	Reserves		
	Legal reserve		
	Statutory reserves	97 449	182 904
	Tax regulated reserves		
	Other reserves		
	Profit and loss account brought forward	-26 495 642	-17 114 468
	Previous results not yet allotted		
	Result for the financial year (profit or loss)	-6 208 060	-9 381 174
Net worth before allocation	3 288 970	8 871 499	
Investment grants			
Special provision for tax purposes			
	Total	3 288 970	8 871 499
Other funds	Subordinated equity		
	Advances subject to covenants	1 210 000	1 257 500
	Total	1 210 000	1 257 500
Provisions	Provisions for risks	276	2 853
	Provisions for future costs	58 526	
	Total	58 802	2 853
Liabilities	Financial liabilities		
	Convertible debenture loans		
	Other debenture loans		
	Borrowing from credit institution	1 248	1 105
	Other borrowings		
	Total	1 248	1 105
	Advances received on orders		
	Trade accounts payable and related liabilities	4 547 996	3 313 429
	Taxes and social debts	506 778	444 509
	Liabilities related to fixed assets		
Other debts	59 833	19 156	
Cash instruments			
Total	5 114 608	3 777 095	
Income recorded in advance			
Total liabilities and income recorded in advance	5 115 856	3 778 200	
Exchange rate differences liabilities	752	7 076	
TOTAL LIABILITIES	9 674 382	13 917 130	
Leasing for buildings			
Leasing for other equipment			
Non expired discounted notes receivable			

Quantum Genomics

Periods 01/01/2017 30/06/2017 Length 6 months
01/01/2018 30/06/2018 6 months

		France	Export	Total	Previous period
Operating income	Sales of purchased goods				
	Sales of manufactured goods				
	Sales of services				
	Net sales				
	Changes in stock of manufactured goods and work in progress				
	Production of fixed assets capitalised				
	Partial profits on long term contracts				
	Trading incentive grants				
	Write back of depreciation, provisions and transferred charges			62 140	8 356
	Other income			3 684	2
	Total			65 824	8 359
Operating expenses	Goods Purchases				
	Change in inventory				
	Raw materials and other supplies Purchases			76 257	7 122
	Change in inventory			105 356	561 834
	Other purchases and expenses			5 337 970	2 608 648
	Taxes			9 216	17 192
	Wages and salaries			734 801	754 934
	Social security charges			472 272	521 484
	Depreciation and Provisions	• on fixed assets	Depreciation	11 167	14 131
		• on current assets: provisions	Provisions		
	• for risks and future costs: provisions		58 526		
Other expenses			70 375	24 005	
	Total			6 875 943	4 509 353
	Operating result A			-6 810 118	-4 500 993
Joint venture oper.	Profit attributed or loss transferred B				
	Loss attributed or profit transferred C				
Financial income	From shares in group companies				
	From other investments				
	Interests and similar incomes			10 519	17 887
	Write back of provisions and transferred charges			93 502	1 478
	Exchange gain				2 303
Net profit on disposals of current financial investments					
	Total			104 021	21 669
Financial expenses	Increase of provisions against financial assets			104 162	154 101
	Interests payable and similar charges				
	Exchange loss				1 301
	Net losses on disposals of current financial investments				
	Total			104 162	155 402
	Net financial result D			-140	-133 733
RESULT OF ORDINARY OPERATIONS BEFORE CORPORATE TAX ON PROFIT (±A+B-C±D) E				-6 810 259	-4 634 727
Exceptional income	On operating items			33 193	
	On capital items				127 674
	Write back of provisions and transferred charges				
	Total			33 193	127 674
Exceptional expenses	On operating items			3 213	815
	On capital items			90 836	79 559
	Depreciation and provisions				75 000
	Total			94 050	155 374
	Net exceptional result F			-60 856	-27 700
	Employees' profit sharing plan G				
	Corporate tax on profit H			-663 056	-624 865
PROFIT AND LOSS (±E±F-G-H)				-6 208 060	-4 037 562

QUANTUM GENOMICS

Cash flow statement K€	S1 2018	2017	2016
Net income	-6 208	-9 381	-5 241
Non-cash adjusting entries	25	173	28
Net income non-cash entries corrected	-6 183	-9 208	-5 213
Change in inventories	105	767	-997
Change in Account Receivables			
Change in Account Payables	1 235	1 101	801
Change in Tax and employee-related payables	62	-40	172
Change in Other Liabilities and Deferred Income	41	1	-60
Change in Other Receivables and Prepaid Expenses	-930	-598	-233
Need for working capital variation	513	1 231	-318
CASH FLOW FROM OPERATIONS	-5 670	-7 977	-5 531
Intangible assets acquisition		40	-42
Tangible assets acquisition	-14	-8	-25
Financial assets acquisition	-9	114	-142
CASH FLOW FROM INVESTEMENT	-23	146	-208
Capital increase (net of related costs)	623	7 733	7 744
New loans and contributions in current account			
Repayments of loans and current account		-10	
Various (including BPI France advance)	-48		540
Cash from funding	575	7 723	8 284
Cash - start of the period	11 089	11 198	8 652
Cash - end of the period	5 971	11 089	11 197
Cash variation	-5 118	-108	2 545